NEW
YORK, March 12, 2025 /PRNewswire/
-- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:
ATNM) (Actinium or the Company), a pioneer in the development of
targeted radiotherapies, today announced it will participate at the
37th Annual Roth Conference on March 16th to 18th.
Actinium management will be in attendance during the conference
and will be available for 1-on-1 meetings on March 17th and 18th.
Interested investors should contact their ROTH representative or
submit a registration request at Roth2025Registration.
About Actinium Pharmaceuticals, Inc.
Actinium is a pioneer in the development of targeted
radiotherapies intended to meaningfully improve patient outcomes.
Actinium is advancing its lead product candidate Actimab-A, a CD33
targeting therapeutic, as potential backbone therapy in acute
myeloid leukemia (AML) and other myeloid malignancies leveraging
the mutation agnostic alpha-emitter radioisotope payload
Actinium-225 (Ac-225). Actimab-A has demonstrated potential
activity in relapsed and refractory acute myeloid leukemia (r/r
AML) patients in combination with the chemotherapy CLAG-M including
high rates of Complete Remissions (CR) including measurable
residual disease (MRD) negativity with improved survival outcomes
and is being advanced to a Phase 2/3 trial. In addition, Actinium
is engaged with the National Cancer Institute (NCI) under the
Cooperative Research and Development Agreement (CRADA) for
development of Actimab-A in AML and other myeloid malignancies. The
first clinical trial under the CRADA will evaluate the triplet
combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an
oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka
holdings company) a novel oral hypomethylating agent (HMA) in
frontline acute myeloid leukemia (AML) patients. Iomab-ACT,
Actinium's next generation conditioning candidate, is being
developed with the goal of improving patient access and outcomes
for potentially curative cell and gene therapies. Iomab-B is an
induction and conditioning agent prior to bone marrow transplant in
patients with r/r AML, which Actinium is seeking a potential
strategic partner for in the U.S. In addition, the company's
R&D efforts are primarily focused on advancing several
preclinical programs for solid tumor indications. Actinium holds
230 patents and patent applications including several patents
related to the manufacture of the isotope Ac-225 in a
cyclotron.
For more information, please
visit: https://www.actiniumpharma.com/
Forward-Looking Statements
This press release may contain projections or other
"forward-looking statements" within the meaning of the
"safe-harbor" provisions of the private securities litigation
reform act of 1995 regarding future events or the future financial
performance of the Company which the Company undertakes no
obligation to update. These statements are based on management's
current expectations and are subject to risks and uncertainties
that may cause actual results to differ materially from the
anticipated or estimated future results, including the risks and
uncertainties associated with preliminary study results varying
from final results, estimates of potential markets for drugs under
development, clinical trials, actions by the FDA and other
governmental agencies, regulatory clearances, responses to
regulatory matters, the market demand for and acceptance of
Actinium's products and services, performance of clinical research
organizations and other risks detailed from time to time in
Actinium's filings with the Securities and Exchange Commission (the
"SEC"), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms
8-K, each as amended and supplemented from time to time.
Investors:
investorrelations@actiniumpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-participate-at-the-37th-annual-roth-conference-302399382.html
SOURCE Actinium Pharmaceuticals, Inc.
